ebola
viru
diseas
evd
acut
sever
ill
often
fatal
untreat
origin
viru
unknown
fruit
bat
pteropodida
nonhuman
primat
consid
potenti
host
ebola
viru
ebov
evd
initi
discov
name
ebola
river
yambuku
democrat
republ
congo
first
seri
case
occur
previou
evd
outbreak
local
remot
area
central
africa
recent
epidem
west
africa
spread
rural
even
urban
area
evd
fatal
rate
report
past
outbreak
rang
current
ebola
outbreak
west
africa
first
case
report
march
seriou
extens
outbreak
sinc
ebov
discov
number
incid
case
death
greater
outbreak
histori
sever
affect
countri
includ
guinea
sierra
leon
liberia
surviv
long
period
conflict
instabl
equip
fragil
health
system
shorthand
human
infrastructur
resourc
novemb
ebola
case
death
report
eight
affect
countri
includ
guinea
liberia
mali
sierra
leon
nigeria
seneg
spain
unit
state
america
total
healthcar
worker
hcw
infect
evd
novemb
die
notabl
evid
current
ebola
epidem
previou
outbreak
strongli
suggest
follow
epidemiolog
featur
ebov
nonairborn
transmit
cough
sneez
primari
transmiss
rout
direct
contact
contamin
fluid
broken
skin
mucou
membran
howev
question
still
remain
concern
vomit
diarrheal
fluid
interestingli
famili
america
first
diagnos
ebola
patient
acquir
infect
despit
common
resid
patient
alreadi
vomit
diarrhea
due
lack
suffici
research
hard
scientif
evid
still
rare
current
assert
rout
transmiss
primarili
base
observ
epidemiologist
ebov
belong
famili
filovirida
taxonom
group
envelop
nonseg
negativestrand
rna
virus
kb
rna
genom
filovirida
viru
famili
includ
three
genera
cueva
viru
marburg
viru
ebov
ebola
virion
uniform
diamet
nm
length
nm
envelop
put
deriv
host
cell
membran
bind
nm
diamet
nucleocapsid
ebov
compos
five
differ
speci
bundibugyo
sudan
ivoir
reston
first
three
speci
ebov
link
outbreak
africa
wherea
ivoir
reston
subspeci
associ
ebola
hemorrhag
fever
ehf
human
outbreak
date
viru
respons
west
african
outbreak
belong
speci
genom
ebov
encod
seven
polyprotein
one
nonstructur
protein
includ
glycoprotein
gp
nucleoprotein
np
rnadepend
rna
polymeras
l
virion
protein
vp
secret
glycoprotein
sgp
ebov
genom
rel
simpl
molecular
basi
ebov
interact
host
cell
remain
unclear
mechan
ebov
infect
cell
might
reli
two
type
glycoprotein
either
secret
transmembran
form
yang
et
al
observ
sgp
interact
neutrophil
inhibit
earli
neutrophil
activ
wherea
transmembran
glycoprotein
interact
endotheli
cell
like
contribut
hemorrhag
symptom
diseas
addit
matrix
protein
ebov
might
play
role
format
surround
envelop
viru
assembl
bud
howev
might
involv
transcript
replic
ebola
np
primari
structur
protein
associ
filoviru
nucleocapsid
fortun
date
evid
shown
mutat
could
significantli
alter
virul
spread
pathogen
ebov
pathogenesi
evd
remain
unclear
incub
period
ebov
may
depend
infect
rout
eg
day
inject
versu
day
contact
migrat
ebov
origin
primari
site
infect
region
lymph
node
follow
vascular
spread
bloodstream
dendrit
cell
macrophag
within
liver
spleen
thymu
lymphoid
tissu
infect
host
mucos
membran
broken
skin
parent
transmiss
circul
ebov
infect
sever
cell
type
includ
monocyt
macrophag
dendrit
cell
endotheli
cell
hepatocyt
epitheli
cell
although
lymphocyt
known
resist
ebov
undergo
apoptosi
lead
decreas
lymphocyt
count
infer
drawn
cell
might
express
entri
receptor
ebov
replic
filovirus
widespread
macrophag
dendrit
cell
name
sentinel
cell
result
necrosi
releas
abund
new
viral
particl
extracellular
fluid
meanwhil
hepatocyt
destroy
necrosi
occur
lead
dysregul
clot
factor
even
coagulopathi
adrenocort
necrosi
also
observ
caus
hypotens
impair
steroid
synthesi
addit
caus
extens
tissu
damag
ebov
also
trigger
macrophag
monocyt
cell
releas
cocktail
cytokin
chemokin
seri
proinflammatori
cytokin
tumor
necrosi
factoralpha
interleukin
il
macrophag
chemotact
protein
mcp
nitric
oxid
destroy
vascular
endothelium
also
activ
coagul
cascad
interestingli
ebov
impair
antigenspecif
immun
respons
direct
indirect
way
filovirus
caus
sever
frequent
fatal
ill
partial
due
damag
dendrit
cell
function
promot
lymphocyt
apoptosi
function
dendrit
cell
bear
primari
respons
start
adapt
immun
respons
major
site
replic
filovirus
accord
sever
vitro
investig
studi
infect
dendrit
cell
fail
present
antigen
naiv
lymphocyt
attribut
lack
matur
cell
develop
result
suggest
underli
mechan
patient
die
evd
may
develop
antibodi
viru
moreov
attrit
lymphocyt
anoth
phenomenon
observ
lethal
ebov
infect
although
lymphocyt
directli
infect
ebov
overal
system
infect
induc
massiv
bystand
apoptosi
ebov
infect
result
multiorgan
failur
shock
appear
caus
clot
disord
vascular
leakag
two
stimulu
factor
coagul
defect
virusinfect
macrophag
synthes
cellsurfac
tissu
factor
tf
happen
simultan
may
contribut
rapid
progress
critic
sever
coagulopathi
involv
ebov
infect
former
event
appear
trigger
indirectli
host
inflammatori
respons
latter
activ
extrins
coagul
pathway
moreov
proinflammatori
cytokin
also
induc
macrophag
produc
tf
addit
factor
activ
protein
c
platelet
may
also
involv
coagul
defect
evd
studi
hotchkiss
rs
colleagu
show
ebovinfect
macaqu
level
activ
protein
c
begin
decreas
day
two
post
infect
platelet
count
decreas
three
four
day
follow
infect
indic
activ
platelet
adher
endotheli
cell
throughout
ebv
develop
involv
organ
dysfunct
hepat
injuri
caus
declin
plasma
level
certain
coagul
factor
clinic
symptom
evd
character
acut
sever
multiorgan
involv
definit
incub
period
time
interv
infect
viru
onset
symptom
day
clinic
present
evd
begin
abrupt
onset
fever
character
initi
nonspecif
flulik
ill
fever
headach
malais
myalgia
sore
throat
gastrointestin
symptom
nausea
vomit
diarrhea
abdomin
pain
electrolyt
derang
mostli
secondari
diarrhea
vomit
sever
hypokalemia
along
moder
degre
hypocalcaemia
hypomagnesaemia
report
addit
capillari
leakag
combin
intraven
volum
resuscit
commonli
result
signific
third
space
peripher
edema
although
cough
occur
primari
featur
ill
hiccup
dysphagia
often
present
sever
associ
discomfort
hemorrhag
manifest
occur
less
clinic
case
case
rel
sever
poor
outcom
primari
caus
death
typic
hypovolem
shock
due
orogastr
loss
third
space
hemorrhag
relat
sever
electrolyt
abnorm
renal
failur
frequent
late
phase
sever
diseas
prompt
accur
diagnosi
ebola
case
essenti
curb
ebola
outbreak
differenti
diagnosi
evd
take
account
acut
filoviru
diseas
well
infecti
diseas
similar
clinic
manifest
malaria
typhoid
fever
laboratori
screen
diagnosi
technolog
ebov
limit
gener
reliabl
earli
leukopenia
lymphopenia
atyp
lymphocytosi
elev
ast
alp
main
laboratori
abnorm
indic
evd
prothrombin
partial
thromboplastin
time
prolong
detect
fibrin
split
product
indic
dissemin
intravascular
coagul
singl
laboratori
test
yield
definit
diagnosi
ebov
infect
definit
diagnosi
ebov
infect
made
laboratori
test
includ
antibodycaptur
enzymelink
immunosorb
assay
elisa
antigencaptur
detect
test
serum
neutral
test
revers
transcriptas
polymeras
chain
reaction
assay
rtpcr
electron
microscopi
viru
isol
cell
cultur
necessari
among
method
rtpcr
one
rapid
power
tool
diagnosi
filoviru
infect
laboratori
test
perform
adher
appropri
laboratori
safeti
guidelin
maximum
biolog
contain
condit
biosafeti
level
laboratori
util
laboratori
test
regardless
whether
sampl
inactiv
sampl
patient
acut
sera
postmortem
tissu
specimen
materi
collect
ecolog
investig
extrem
biohazard
risk
therefor
maximum
feasibl
precaut
mask
respir
glove
gown
requir
collect
sampl
may
contain
filovirus
septemb
provid
interim
infect
control
recommend
address
patient
care
wast
manag
dispos
human
remain
measur
chines
scientist
develop
sever
detect
kit
ebov
august
includ
fluoresc
rtpcr
nucleic
acid
detect
kit
colloid
gold
immun
chromatographi
antigen
detect
kit
elisa
antigen
detect
kit
use
laboratori
examin
ebola
past
sever
year
progress
develop
potenti
vaccin
ebov
made
progress
develop
antivir
drug
postexposur
intervent
much
slower
retriev
cortelli
databas
thomson
reuter
combin
knowledg
ebov
analyz
current
r
medicin
vaccin
evd
studi
find
show
mainli
five
import
categori
vaccin
neutral
antibodi
smallmolecul
antiebola
drug
rna
interfer
rnai
drug
nucleotid
drug
categori
promis
product
develop
worthi
attent
due
lack
effect
drug
avail
evd
support
treatment
complic
septic
shock
hematolog
abnorm
hypovolemia
refractori
shock
hypoxia
electrolyt
abnorm
hemorrhag
multiorgan
failur
dic
emphas
sever
ill
patient
requir
intens
support
care
evd
patient
oral
antiemet
antidiarrh
therapi
adequ
rehydr
essenti
addit
infect
prevent
control
measur
critic
part
clinic
manag
although
robust
data
still
lack
clinic
experi
evd
patient
treat
current
outbreak
suggest
mortal
rate
associ
evd
significantli
reduc
provis
support
care
particular
critic
care
ebola
epidem
receiv
experiment
drug
call
zmapp
two
american
aid
worker
fell
sick
evd
liberia
surviv
success
zmapp
develop
san
diegobas
privat
biotech
firm
mapp
biopharmaceut
previou
studi
suggest
zmapp
suppli
best
option
experiment
therapeut
use
treat
ebovinfect
patient
potenti
treatment
includ
monoclon
antibodi
administr
small
inhibitori
rna
molecul
still
scientif
investig
date
vaccin
licens
two
potenti
effect
vaccin
enter
stage
human
safeti
test
rvsvzebov
first
vaccin
compos
chimpanzeederiv
adenoviru
vector
ebov
gene
insert
vaccin
jointli
develop
glaxosmithklin
us
nation
institut
allergi
infecti
diseas
attenu
strain
vesicular
stomat
viru
vsv
pathogen
normal
found
livestock
includ
second
vaccin
one
vsv
gene
replac
ebov
gene
second
vaccin
develop
public
health
agenc
canada
winnipeg
licens
commerci
held
newlink
genet
compani
american
compani
ame
iowa
sinc
aftermath
sever
acut
respiratori
syndrom
outbreak
china
develop
rel
strong
system
accumul
preciou
experi
prevent
control
emerg
infecti
diseas
proven
crucial
effect
control
avian
influenza
epidem
influenza
outbreak
public
health
emerg
face
sever
ebola
epidem
west
africa
china
made
posit
activ
action
provid
aid
prevent
control
ebola
novemb
china
success
provid
four
round
emerg
aid
total
valu
million
yuan
ebolaaffect
countri
medic
staff
china
reach
mantim
sierra
leon
sampl
test
conduct
mobil
laboratori
support
china
account
total
test
accuraci
twothird
intern
antiebola
materi
assist
receiv
guinea
came
china
addit
almost
antiebola
materi
within
ten
countri
surround
epidem
area
offer
china
approxim
peoplecompos
chines
medic
technician
public
health
expert
sent
frontlin
battl
ebola
month
ahead
antiebola
train
plan
involv
medic
worker
commun
staff
soon
initi
china
china
implement
seriou
effect
prevent
control
strategi
exampl
china
control
follow
entri
gateway
ebola
possibl
invad
entri
gateway
china
institut
strict
control
airport
custom
exit
entri
port
strengthen
quarantin
work
port
health
monitor
passeng
ebola
epidem
area
quarantin
isol
control
potenti
infect
sourc
key
measur
prevent
control
ebola
peopl
return
west
african
countri
must
remain
strict
quarantin
peopl
posit
suspici
contact
histori
must
remain
isol
nation
emerg
china
set
strong
infecti
diseas
control
prevent
system
basi
knowledg
acquir
sar
outbreak
follow
sever
public
health
urgenc
medic
care
medic
staff
inform
diseas
natur
inform
bulletin
provid
time
manner
strictli
adher
recommend
infect
control
guidelin
first
aid
ebola
viru
infect
appear
patient
given
symptomat
support
treatment
person
protect
scientif
understand
transmiss
rout
ebola
effect
control
spread
ebola
etiquett
custom
face
highli
contagi
lethal
ebov
chang
handshak
etiquett
avoid
shake
hand
hug
other
environment
sanit
maintain
proper
sanit
key
prevent
control
infecti
diseas
strategi
implement
transmiss
diseas
countri
lessen
addit
tradit
chines
medicin
place
prevent
treat
emerg
infecti
diseas
epidem
chines
medicin
maxingshiganyinqiaosan
formula
show
similar
efficaci
oseltamivir
treat
human
tradit
chines
herbal
therapi
may
consid
treatment
option
ebola
analyz
detail
data
confirm
probabl
ebola
case
collect
guinea
liberia
nigeria
sierra
leon
march
septemb
ebola
respons
team
studi
show
basic
reproduct
number
estim
current
reproduct
number
r
correspond
doubl
time
guinea
day
respect
valu
liberia
day
sierra
leon
day
respect
notabl
susceptibleexposedinfectiousrecov
model
predict
evd
china
mean
total
import
case
data
indic
strengthen
control
measur
implement
evd
case
death
associ
diseas
would
continu
grow
near
futur
sever
current
affect
area
could
even
spread
surround
countri
ebola
epidem
might
last
anoth
month
develop
countri
intern
aid
group
strengthen
support
send
medic
staff
also
help
countri
establish
suitabl
public
health
prevent
control
system
posit
antiebola
respons
action
plan
china
proven
effect
develop
prophylact
vaccin
therapeut
drug
main
focu
next
step
top
intern
pharmaceut
compani
put
drive
profit
asid
join
global
intellig
develop
protect
vaccin
effect
drug
discuss
epidemiolog
featur
pathogenesi
prognosi
outcom
associ
ebola
remain
unclear
therefor
research
conduct
aspect
provid
evid
prevent
control
ebola
genet
mutat
ebov
close
monitor
especi
effect
mutat
virul
transmiss
rout
hope
global
effort
challeng
brought
ebola
outbreak
conquer
near
futur
